NIH R01 · 2025
Project Summary/Abstract Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus endemic in 110 countries that causes febrile illness and arthritic disease. In November 2023, FDA approved the first CHIKV vaccine, a live attenuated vaccine (LAV) marketed as IXCHIQ. Although there are many important human pathogenic alphaviruses with a near global distribution, IXCHIQ is the first alphavirus vaccine licensed for humans. No studies have evaluated the ability of IXCHIQ to protect against infection, viremia, and disease after exposure to other alphaviruses that also occur in Latin America in areas with CHIKV or determined how prior heterologous alphavirus infection impacts IXCHIQ…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.